Clinical observation on rheumatoid arthritis.docVIP

 PAGE \* MERGEFORMAT 8 Clinical observation on rheumatoid arthritis Of: Huang Chuanbing, Mrs, Chen Xi, Chen Xiaowen, Yang Sheng Jie [Keywords:] new air capsules, leflunomide, refractory rheumatoid arthritis Rheumatoid arthritis (RA) is a common chronic inflammation of peripheral joints other than the main manifestations of autoimmune disease, disability is high, seriously affecting the quality of life of patients. Currently, Western medicine is still a lack of effective therapy for RA, a large Some patients receiving non-steroidal anti-inflammatory drugs, corticosteroids, gold preparations, methotrexate, sulfasalazine, chloroquine, or hydroxyl one or more of chloroquine and other drugs in combination therapy, the disease to ease, but also part of the patient’s condition has not been controlled, a refractory rheumatoid arthritis, the prognosis is poor. In recent years, I tried a new style joint capsule of leflunomide treatment, with satisfactory results. are reported below. 1 Materials and Methods 1.1 General Information 21 cases were selected in 2003-2008 rheumatology inpatient hospital, including 17 females, 4 males, the youngest 26 years old, maximum 61 years (mean 36.56 + -9.32) years, the shortest duration of 3 years, the most 9 years longer on average (4.68 + -2.32) years. 1.2 Diagnosis and inclusion criteria Diagnostic criteria: patients are in line with 1987 American College of Rheumatology (ACR) classification criteria for RA [1], the simple disease activity score (DAS28) was 6.4 ~ 6.8 (gt; 5.1 was divided into disease activity). Inclusion criteria: ① age of “60 years old, ② 4 4 or more species or second-line drugs for 6 months continuous treatment ineffective, ③ no serious irreversible damage to internal organs, ④ liver and renal function normal bone marrow function was normal. 1.3 Treatment 21 patients were taking leflunomide, 20 mg / time, 1 time / d, Xinfeng Capsule (Court preparation center), 3 capsules / time, 3 ti